COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19
Latest Information Update: 15 Jun 2023
Price :
$35 *
At a glance
- Drugs Acebilustat (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms Acebilustat Sub-Protocol; COPPS
- 24 May 2023 Results reporting outcomes ; PK, duration of viral shedding, and prolonged symptoms assessed over 120 days presented at the 119th International Conference of the American Thoracic Society
- 30 Mar 2023 Primary endpoint (For Clinical Domain: Time-to-sustained-resolution) has not been met according to Results published in the Clinical Infectious Diseases.
- 30 Mar 2023 Results assessing the effect of acebilustat for treatment of outpatients with mild-moderate COVID-19 disease published in the Clinical Infectious Diseases